Harrow (Harrow) Total Current Liabilities : $49.3 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Harrow Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Harrow's total current liabilities for the quarter that ended in Dec. 2023 was $49.3

Harrow Total Current Liabilities Historical Data

The historical data trend for Harrow's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Total Current Liabilities Chart

Harrow Annual Data

Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

Get a 7-Day Free Trial 12.28 10.80 9.72 18.63 49.34

Harrow Quarterly Data

Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23

Total Current Liabilities Get a 7-Day Free Trial 18.63 17.71 23.01 19.03 49.34

Harrow Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Harrow's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 48.463 + 0.806

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0.075

= 49.3

Harrow's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 48.463 + 0.806

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0.075

= 49.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Harrow Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Harrow's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Harrow (Harrow) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Total Current Liabilities

Comparable Companies

SIGA ESPR PROC PAHC ORGO ALIM PETQ ZOM LFCR EOLS ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX

Traded in Other Exchanges

N/A

Address

102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205

Website

https://www.harrow.com

Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.

Executives

Mark L Baum director, 10 percent owner, officer: Chief Executive Officer C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108

Martin A. Makary director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205

Van Horn R. Lawrence director 354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067

Andrew Boll officer: VP, Accounting and Reporting 437 S HWY 101, STE 209, SOLANA BEACH CA 92075

Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391

Perry J. Sternberg director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205

Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215

Robert J Kammer director, 10 percent owner, officer: Chairman of the Board 1440 28TH STREET, SUITE 9, BOULDER CO 80303

Longboard Capital Advisors, Llc other: Institutional Investor 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212

Brett Conrad other: Managing Mbr of Longboard Cap. 1312 CEDAR ST., SANTA MONICA CA 90405

Clayton D Edwards officer: Chief Operating Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

Anthony Principi director 2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244

Donald Paul Miloni 10 percent owner 1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125

John P. Saharek officer: Chief Commercial Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

Harrow (Harrow) Headlines

From GuruFocus

Harrow Announces New $100 Million Secured Credit Facility with Oaktree
By Business Wire Business Wire • 03-28-2023

Harrow to Launch FDA-Approved IHEEZO� at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
By Business Wire Business Wire • 05-04-2023

HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options
By PRNewswire PRNewswire • 04-22-2023

Harrow Prices $60 Million Public Offering of Common Stock
By Business Wire • 07-19-2023

Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
By Business Wire • 07-26-2023

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis� Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
By Business Wire • 09-26-2023

HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options
By PRNewswire PRNewswire • 04-15-2023

Harrow Announces Availability of VEVYE� (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
By Business Wire • 01-11-2024

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
By Business Wire • 09-29-2023

HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options
By PRNewswire PRNewswire • 03-25-2023

Harrow Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Liabilities	Get a 7-Day Free Trial															18.63	17.71	23.01	19.03	49.34

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	48.463	+	0.806
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	0	+	0.075
	=	49.3

Mark L Baum	director, 10 percent owner, officer: Chief Executive Officer	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence	director	354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll	officer: VP, Accounting and Reporting	437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks	director	40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer	director, 10 percent owner, officer: Chairman of the Board	1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc	other: Institutional Investor	9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad	other: Managing Mbr of Longboard Cap.	1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards	officer: Chief Operating Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi	director	2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni	10 percent owner	1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek	officer: Chief Commercial Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130